---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-015897"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2025-02-21T23:59:59+00:00"
generated_at: "2026-05-26T06:53:10.678215+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protagonist reports Q4 net income $131.7M; cash $559.2M; upcoming Phase 3 readouts in March 2025

## Summary
- Net income of $131.7M in Q4 2024 ($2.11 basic EPS) vs $27.3M in Q4 2023; FY 2024 net income $275.2M vs net loss of $79.0M in FY 2023.
- License & collaboration revenue of $434.4M for FY 2024, up from $60.0M in FY 2023, including $165M milestone from JNJ.
- Cash, equivalents, and marketable securities $559.2M at Dec 31, 2024; plus $165M milestone received Jan 2025; runway through at least end of 2028.
- Topline results for rusfertide Phase 3 VERIFY (polycythemia vera) and icotrokinra Phase 2b ANTHEM (ulcerative colitis) expected in March 2025.
- Nominated PN-881, an oral IL-17 receptor antagonist; plans to nominate oral obesity candidate in Q2 2025 and oral hepcidin candidate in Q4 2025.

## SEC filing metadata
- accession: 0001104659-25-015897
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2025-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/0001104659-25-015897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/tm257151d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-015897
- JSON: https://secwatch.observer/filing/0001104659-25-015897.json
- Plain text: https://secwatch.observer/filing/0001104659-25-015897.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.